Viz.ai

Viz.ai’s mission is to improve access to life-saving treatments.

Viz.ai builds AI Care Pathways to help every patient get the right
care, at the right time.

Co-founded out of Stanford in 2016, Viz.ai has achieved major AI
industry milestones, including the first FDA clearance for AI, two FDA
de novo approvals for AI computer-aided triage and cardiovascular
machine-learning notification software, and 10 additional 510(k)
clearances. Viz.ai was also the first AI company to receive CMS
reimbursement through the New Technology Add-on Payment (NTAP) for AI.

Today, Viz.ai is used in 2,000+ hospitals, serving 230M+ lives across
neurology, cardiology, oncology, pulmonology and other disease areas.